摘要
目的探讨乳腺癌患者化疗后肝功能损伤与乙肝病毒感染之间的相关性,为合并乙肝病毒感染的乳腺癌患者化疗后肝功能损伤的防治提供指导。方法选取宁波妇女儿童医院乳腺外科2012年6月~2016年11月120例接受术后辅助化疗的乳腺癌患者为研究对象,根据是否合并乙肝病毒感染分为研究组与对照组,研究组HBs Ag阳性,共62例;对照组HBV-DNA、HBsAg均阴性,共58例;比较2组患者化疗后肝功能损伤的发生情况及预防性抗病毒治疗对降低合并乙肝病毒感染的乳腺癌患者化疗后肝功能损伤的作用。结果研究组化疗后肝功能损伤发生率48.28%,对照组化疗后肝功能损伤发生率6.45%,研究组化疗后肝功能损伤发生率显著高于对照组,差异有统计学意义（P〈0.05）。研究组肝功能损害中Ⅰ度、Ⅱ度、Ⅲ度、Ⅳ度的程度明显的高于对照组,差异有统计学意义（P〈0.05）。研究组中抗病毒治疗20例,未抗病毒治疗42例。进行抗病毒治疗者HBV再激活率（5.0%与31.0%）和肝功能损伤发生率（20.0%与52.4%）均明显低于未行抗病毒治疗者,差异均有统计学意义（P〈0.05）。结论合并乙肝病毒感染的乳腺癌患者化疗后易发生肝功能损伤,预防性抗病毒治疗能减少化疗后肝功能损伤的发生率和程度。
Objective To investigate the interrelated liver damage and hepatitis B virus infection among breast cancer patients after chemotherapy, to provide guidance for future breast reduction combined hepatitis B virus infection after chemotherapy liver damage.Methods120 cases of breast cancer patients undergoing chemotherapy combined hepatitis B carries from June 2012 to November 2016 in ningbo women and children＇s hospital were selected as the research object, depending on whether the infection with the hepatitis B virus into the study group and the control group, the study group HBV-DNA, HBsAg are positive, totaling 62 cases;control group, HBV-DNA, HBsAg were negative, totaling 58 cases;compare two groups of patients after chemotherapy in cases of liver damage.ResultsThe study group after chemotherapy, the incidence of liver dysfunction 48.28% in the control group after chemotherapy, the incidence of liver dysfunction 6.45 percent, the study group after chemotherapy, the incidence of liver dysfunction was significantly lower than the control group, the difference was statistically significant （P〈0.05）.Study group Ⅰ liver damage degree, degree Ⅱ, degree Ⅲ, degree Ⅳ of apparent higher, the difference was statistically significant （P〈0.05）, antiviral therapy 20 cases, no antiviral treatment in 42 cases.Antiviral therapy HBV reactivation rate and incidence of liver dysfunction were 5.0%, 20.0%;no antiretroviral therapy in HBV reactivation rate and the incidence of liver dysfunction 31.0%, 52.4% respectively;HBV antiviral therapy re-activation rate and the occurrence of liver dysfunction were significantly lower than not antiviral therapy, and the data were statistically significant （P〈0.05）.ConclusionThe clinical having close links between liver damage and breast cancer combined hepatitis B virus infection with hepatitis B virus are more likely to occur after infection liver dysfunction chemotherapy, and breast cancer patients after chemotherapy.
出处
《中国生化药物杂志》
CAS
2017年第5期428-429,432,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
乳腺癌
乙肝病毒感染
肝功能损伤
相关性
breast cancer
hepatitis B virus infection
liver dysfunction
correlation
